Adicet Bio (ACET) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.

• Pipeline includes “off-the-shelf” gamma delta T cells engineered with chimeric antigen receptors (CARs) for durable patient activity.

• Lead candidate prulacabtagene leucel (prula-cel) targets CD20 for autoimmune diseases; ADI-212 targets PSMA in prostate cancer.

• Manufacturing process enables rapid, cost-efficient production from unrelated donors, avoiding graft versus host response.

• Offices in Boston, MA and Redwood City, CA; listed on Nasdaq under symbol "ACET."

Financial performance and metrics

• Classified as a "smaller reporting company" with less than $250 million in public float or less than $100 million in annual revenues and less than $700 million in public float.

• Utilizes scaled disclosure and reporting requirements, including reduced executive compensation disclosures and fewer years of audited financials.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including R&D, clinical trials, manufacturing, working capital, and capital expenditures.

• Proceeds may be temporarily invested in investment grade, interest-bearing instruments and U.S. government securities.

• Management retains broad discretion over allocation of net proceeds.